Repatha Cost in Nebraska 2026: Cash Pay, Medicaid, Insurance, and Compounded Options

What Does Repatha Actually Cost in Nebraska in 2026?

The sticker price for Repatha in Nebraska sits at approximately $580 per month, which reflects Amgen's published wholesale acquisition cost for either the 140 mg every-two-weeks dosing schedule or the 420 mg once-monthly SureClick autoinjector. That figure has remained broadly stable into 2026 after a list-price cut Amgen made in 2023. Without insurance or manufacturer assistance, a Nebraska patient would pay close to $6,960 annually at retail pharmacies in Omaha, Lincoln, or anywhere across the state.

The gap between list price and what patients actually pay is wide, and the path each patient takes through it depends on three things: their insurance status, their income, and whether they are willing to explore compounded alternatives. None of those paths are automatic. Each requires a specific action from the prescribing clinician and the patient.

Evolocumab belongs to the PCSK9 inhibitor drug class. It works by blocking proprotein convertase subtilisin/kexin type 9, a protein that degrades LDL receptors in the liver. With fewer receptors destroyed, the liver clears more LDL-C from circulation. In the FOURIER cardiovascular outcomes trial (N=27,564), semaglutide's lipid-lowering cousin produced a 59% mean reduction in LDL-C from baseline versus placebo, and the primary composite endpoint of major adverse cardiovascular events fell by 15% (HR 0.85 to 95% CI 0.79, 0.92, P<0.001) over a median 2.2 years of follow-up. [1]

The American College of Cardiology/AHA 2018 Cholesterol Guideline states: "In patients with very high-risk ASCVD, use of a PCSK9 inhibitor is recommended if LDL-C remains 70 mg/dL or higher on maximally tolerated statin plus ezetimibe therapy." [2] That clinical threshold is the single most important line a Nebraska patient can bring to a prior-authorization appeal.

Nebraska Medicaid Coverage for Repatha: The Current Status

Nebraska Medicaid does not cover Repatha as of 2026. Nebraska's Medicaid program, administered through Nebraska's Division of Medicaid and Long-Term Care under the Health and Human Services umbrella, has not added evolocumab or alirocumab to its preferred drug list for outpatient use.

This matters for roughly 340,000 Nebraskans enrolled in Medicaid, a number that grew after the state expanded Medicaid under Proposition 432 in 2020. Patients with familial hypercholesterolemia or established atherosclerotic cardiovascular disease who are on the Medicaid program and cannot tolerate statins at sufficient doses face a genuine access gap.

Practical steps for Medicaid patients in Nebraska right now:

1. Request a prior authorization appeal through your prescriber, citing the ACC/AHA guideline threshold above.
2. Ask your cardiologist or lipidologist to document statin intolerance or inadequate LDL response with lab values attached.
3. Explore the Amgen Repatha PCSK9 Patient Assistance Program (PAP), which offers free drug to qualifying patients regardless of insurance status, based on income criteria. [3]
4. Discuss compounded evolocumab with a telehealth prescriber (see the compounding section below).

Nebraska Medicaid formulary decisions are reviewed annually. The state's Pharmacy and Therapeutics Committee has the authority to add PCSK9 inhibitors if cost-effectiveness data or federal rebate negotiations change the calculus. The Institute for Clinical and Economic Review (ICER) published an updated assessment in 2023 finding that evolocumab is cost-effective at prices at or below $4,500 per year for very-high-risk ASCVD patients, a threshold still above the current net price after rebates for most state Medicaid programs. [4]

How Commercial Insurance Covers Repatha in Nebraska

Most commercial insurance plans available in Nebraska, including Blue Cross Blue Shield of Nebraska, Medica, and UnitedHealthcare plans sold on the ACA marketplace, place Repatha on a specialty tier. That typically means a prior authorization is required, and step-therapy criteria often demand documentation that the patient has tried and failed at least two statins at maximum tolerated doses, plus ezetimibe in many cases.

The prior-authorization process is where most Nebraska patients stall. A 2021 analysis published in JAMA Cardiology found that only 55.6% of PCSK9 inhibitor prior-authorization requests were ultimately approved, and the median time from initial submission to approval was 11 days, with some cases taking over 30 days. [5] Your prescriber's office can accelerate this by submitting the following with the initial PA request:

• Most recent fasting lipid panel (dated within 90 days)
• Documentation of maximally tolerated statin dose and duration
• Documentation of statin intolerance if applicable, including CK levels or symptom log
• Evidence of established ASCVD or confirmed FH diagnosis (Dutch Lipid Clinic Network score or genetic testing result)
• Direct quotation from the ACC/AHA guideline noting the 70 mg/dL threshold for very-high-risk patients

Once approved, most Nebraska commercial plans cover Repatha at the specialty copay tier. The Amgen savings card can then offset that copay to near zero for eligible commercially insured patients.

The Amgen Repatha Savings Card: How It Works in Nebraska

The Amgen Repatha Copay Card program allows commercially insured patients to pay as little as $0 per month, with Amgen covering up to the remainder of the copay or coinsurance. As of 2026, the program cap is up to $4,700 per year per patient. [3]

Eligibility rules are specific. Patients must be covered by commercial or private insurance, must be a resident of the United States, and must not be enrolled in any federal or state government insurance program, including Medicare Part D or Medicaid. Nebraska Medicare beneficiaries are therefore not eligible. For Medicare patients, the Extra Help / Low Income Subsidy program and the Amgen Patient Assistance Program (which provides free drug based on income, not insurance type) are the two main avenues.

To enroll in Nebraska:

1. Visit Amgen's savings program portal or call 1-844-REPATHA.
2. Complete the enrollment form, which requires the prescriber NPI number and insurance information.
3. Present the card at any Nebraska retail pharmacy that carries specialty biologics. Major chains in Omaha and Lincoln carry it; smaller rural pharmacies may require a special order.

The card renews annually. Patients should re-enroll each January 1 to avoid a gap in coverage.

Compounded Evolocumab in Nebraska: What Is Legal and What Is Not

Compounded evolocumab is legal in Nebraska when prepared by a licensed 503A compounding pharmacy. Here is what that distinction means in practice.

The FDA distinguishes two categories of compounding pharmacies under the Drug Quality and Security Act of 2013. A 503A pharmacy compounds for individual patients based on a valid prescription from a licensed prescriber. A 503B outsourcing facility compounds in larger batches without patient-specific prescriptions and is subject to FDA Current Good Manufacturing Practice (cGMP) regulations. [6]

Nebraska has licensed 503A pharmacies that compound peptide-based and biologic-adjacent preparations. Evolocumab is not an FDA-approved compoundable drug in the sense that it does not appear on any FDA shortage list, and the FDA has issued guidance cautioning that PCSK9 inhibitor biologics present specific challenges for compounding because replicating tertiary protein structure outside pharmaceutical-grade manufacturing conditions is technically demanding. [6]

The legal framework for Nebraska patients and prescribers therefore looks like this:

• A licensed Nebraska prescriber may write a prescription for compounded evolocumab for an individual patient.
• A licensed 503A pharmacy in Nebraska may fill that prescription.
• The resulting compound is not FDA-approved and carries no Amgen bioequivalence guarantee.
• The prescriber bears responsibility for the clinical decision and must document the rationale.

The cost difference is the central appeal. Compounded evolocumab from a 503A pharmacy in Nebraska can cost substantially less than the $580/month list price for brand-name Repatha, with some pharmacies pricing it between $100 and $250 per month depending on dose and compounding fees. Cash-pay patients who cannot access the Amgen savings card (Medicare enrollees, for example) or who have been denied coverage by Nebraska Medicaid will find this the most accessible price point.

Patients considering compounded evolocumab should ask their prescriber or pharmacist the following questions before proceeding:

1. What concentration and vehicle is used in the preparation?
2. Does the pharmacy hold a current Nebraska State Board of Pharmacy license?
3. Has the pharmacy conducted sterility and potency testing on recent batches?
4. What is the cold-chain shipping protocol if the pharmacy ships to a rural Nebraska address?

Subcutaneous biologic injections require proper refrigeration. Evolocumab, whether brand or compounded, should be stored at 36 to 46 degrees Fahrenheit and allowed to reach room temperature for 30 minutes before injection.

Telehealth Prescribing of Repatha in Nebraska

Telehealth prescribing of Repatha is permitted in Nebraska. The state's telehealth parity law (Nebraska Revised Statute 44-7,100) requires most commercial insurers to cover telehealth services at parity with in-person visits, and the state did not reimpose pre-pandemic restrictions on remote prescribing of non-controlled medications after the federal public health emergency ended. [7]

For evolocumab specifically, the clinical workflow via telehealth typically runs as follows:

1. Initial intake visit: The telehealth clinician reviews fasting lipid panels, prior statin trial history, and cardiovascular risk documentation uploaded by the patient or transferred from the primary care record.
2. Prescribing decision: The clinician issues a prescription for evolocumab or, where clinically appropriate and the patient meets criteria, for compounded evolocumab from a 503A partner pharmacy.
3. Prior authorization support: The telehealth practice handles PA submission and appeal correspondence with the insurer.
4. Follow-up at 8 to 12 weeks: A repeat fasting lipid panel is ordered to confirm LDL-C response. The 2018 ACC/AHA guideline recommends a follow-up lipid panel 4 to 12 weeks after initiating or adjusting PCSK9 inhibitor therapy. [2]

HealthRX clinicians can manage this entire workflow remotely for Nebraska patients, including rural patients in counties like Cherry, Kimball, or Dundy where access to a local lipidologist may require a drive of more than 90 minutes.

LDL-C Targets and When Evolocumab Is the Right Choice

Not every Nebraskan with elevated LDL-C needs evolocumab. The drug is most clearly indicated for two groups:

Group 1: Established ASCVD with LDL-C 70 mg/dL or higher on maximum tolerated statin plus ezetimibe. This includes patients who have had a prior MI, stroke, symptomatic peripheral arterial disease, or who have undergone coronary revascularization. The FOURIER trial enrolled exactly this population, and the 15% relative risk reduction in the composite endpoint translated to an absolute risk reduction of 1.5 percentage points over 2.2 years, a number that carries greater clinical weight in patients with higher baseline event rates. [1]

Group 2: Heterozygous or homozygous familial hypercholesterolemia. The RUTHERFORD-2 trial (N=329) showed that evolocumab 140 mg every two weeks reduced LDL-C by 59.2% from baseline in HeFH patients at 12 weeks versus a 0.5% reduction with placebo (P<0.001). [8] In homozygous FH, where LDL receptor activity may be near zero, response is more variable and depends on residual receptor function.

Patients who are statin-naive or who have not yet tried high-intensity statin therapy (rosuvastatin 20 to 40 mg/day or atorvastatin 40 to 80 mg/day) are typically not candidates for PCSK9 inhibitor therapy until those steps have been documented. This is partly clinical (statins reduce LDL by 40 to 50% and cost under $10/month generic) and partly insurance-driven: no Nebraska commercial plan will approve Repatha without statin trial documentation.

Ezetimibe 10 mg/day, which costs roughly $10 to $30/month generic, should also be documented as trialed before a PCSK9 inhibitor PA is submitted, unless contraindicated. Combining high-intensity statin, ezetimibe, and evolocumab can reduce LDL-C by 65 to 85% from baseline, bringing most very-high-risk patients well below the 55 mg/dL threshold recommended for secondary prevention by the 2019 ESC/EAS dyslipidemia guidelines. [9]

Comparing Your Cost Options as a Nebraska Patient

The table below summarizes the realistic monthly cost scenarios for a Nebraska patient in 2026:

| Scenario | Estimated Monthly Cost | |---|---| | Uninsured, no assistance | ~$580 | | Commercial insurance, no savings card | Specialty copay: $50 to $200 | | Commercial insurance plus Amgen savings card | $0 to $10 | | Medicare Part D, Extra Help tier | ~$0 to $35 depending on plan | | Medicare Part D, no Extra Help | $100 to $400 depending on plan | | Nebraska Medicaid | Not covered | | Amgen PAP (low income, uninsured) | $0 | | Compounded 503A pharmacy (cash pay) | ~$100 to $250 |

For the approximately 12% of Nebraska adults who are uninsured (per CDC Behavioral Risk Factor Surveillance System data), the Amgen PAP and compounded evolocumab represent the two financially viable paths. [10] The PAP requires an annual income at or below 600% of the federal poverty level and documentation from the prescriber.

Injection Technique and Storage for Nebraska Patients

Evolocumab is self-administered via subcutaneous injection using either the SureClick autoinjector (140 mg per 1 mL) or the Pushtronex system (420 mg per 3.5 mL for once-monthly dosing). Both are stored in the refrigerator at 36 to 46 degrees Fahrenheit.

Nebraska's climate matters here. Patients in western Nebraska counties where summer temperatures regularly exceed 95 degrees Fahrenheit should not leave autoinjectors in a vehicle or uninsulated mail drop. If a pen has been left at room temperature for more than 30 days, it should be discarded per Amgen's labeling. [3]

Common injection sites: abdomen, thigh, or upper arm. Rotate sites to reduce local reactions. The most common adverse effects reported in FOURIER were nasopharyngitis (9.3%) and injection-site reactions (2.1%), both comparable to placebo. [1] Serious adverse events were not statistically different from placebo over 2.2 years.

Nebraska-Specific Resources and Next Steps

Nebraska patients seeking evolocumab have a defined set of actions to take, depending on their situation:

If you have commercial insurance: Ask your prescriber to submit a PA with full statin-trial documentation. Enroll in the Amgen savings card at 1-844-REPATHA at the same time the PA is filed.

If you are on Nebraska Medicaid: Request a PA appeal with ACC/AHA guideline language. Ask your prescriber to contact the Nebraska Division of Medicaid about the exceptions process. Separately, apply for the Amgen PAP at amgensupportplus.com. [3]

If you are on Medicare: You are not eligible for the Amgen savings card. Apply for Extra Help through the Social Security Administration if your income is at or below 150% of the federal poverty level. Ask your prescriber about compounded evolocumab as a cost-reduction option.

If you are uninsured or pay cash: Apply for the Amgen PAP first. If you do not qualify on income, ask your HealthRX clinician about a licensed 503A compounding pharmacy.